Notification That Annual Report Will Be Submitted Late (nt 10-k)
November 29 2017 - 1:44PM
Edgar (US Regulatory)
|
SEC
FILE NUMBER
|
|
0001449447
|
|
CUSIP
NUMBER
|
|
29383T
201
|
U.S.
SECURITIES AND EXCHANGE COMMISSION
|
Washington,
D.C. 20549
|
|
FORM
12b-25
|
|
NOTIFICATION
OF LATE FILING
|
|
☒ Form
10-K
|
☐ Form
20-F
|
☐ Form
11-K
|
☐ Form
10-Q
|
☐ Form
10-D
|
☐ Form
N-SAR
|
☐ Form N-CSR
|
|
|
|
|
|
For period
ended:
|
August 31, 2017
|
|
☐ Transition
Report on Form 10-K
|
☐ Transition
Report on Form 20-F
|
☐ Transition
Report on Form 11-K
|
☐ Transition
Report on Form 10-Q
|
☐ Transition
Report on Form N-SAR
|
|
For the
Transition Period Ended: N/A
|
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein
.
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART
I - REGISTRANT INFORMATION
Entest BioMedical, Inc.
|
|
Full Name of Registrant
|
|
|
|
|
|
Former Name if Applicable
|
|
|
|
4700 Spring Street, Suite 304
|
|
Address of Principal Executive Officer
(Street and Number)
|
|
|
|
La Mesa, CA 91942
|
|
City, State and Zip Code
|
|
PART
II - RULES 12b-25 (b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed.
|
(a)
|
The reasons
described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
☒
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-SAR or Form N-CSR, or
portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly
report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof, will be filed on
or before the fifth calendar day following the prescribed due date; and
|
|
(c)
|
The accountant’s
statement or other exhibit required by Rule 12b-25(c) has been attached, if applicable.
|
PART
III - NARRATIVE
The
Company could not complete the filing of its Annual Report on Form 10-K for the period ended August 31, 2017 due to
a delay in obtaining the required accountant’s audit report on the financial statements required to be
included in the Company's Form 10-K, which delay could not be eliminated by the Company without unreasonable effort and expense.
In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, as amended, the Company will file its Form 10-K no later
than the fifteenth calendar day following the prescribed due date.
PART
IV - OTHER INFORMATION
(1)
Name
and telephone number of person to contact in regard to this notification:
|
|
|
|
|
|
David
Koos
|
|
(619)
|
|
702-1404
|
(Name)
|
|
(Area
Code)
|
|
(Telephone
Number)
|
(2)
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the
Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required
to file such report(s) been filed? If answer is no, identify report(s).
|
(3)
Is it
anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will
be reflected by the earnings statements to be included in the subject report or portion thereof?
|
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made.
|
|
|
|
Entest
BioMedical, Inc.
|
|
|
(Name
of Registrant as Specified in Charter)
|
|
Has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November
29, 2017
|
By:
|
/s/
David Koos
|
|
|
David
Koos
President
& CEO
|
Entest (CE) (USOTC:ETNI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Entest (CE) (USOTC:ETNI)
Historical Stock Chart
From Apr 2023 to Apr 2024